Fig. 4.
Fig. 4. Human PAI-1 plasma levels in mice treated with AdCMV-PAI-1 gene transfer. BALB/c nude mice bearing intraocular OCM-1 human uveal melanomas were treated with either two IC inoculations of either AdCMV-βGal or AdCMV-PAI-1 on days 7 and 9 post IC tumor inoculation or three IV inoculations of either AdCMV-PAI-1 or AdCMV-βGal on days 21, 28, and 35 post IC tumor inoculation. BALB/c nude mice bearing intraocular 99E1 melanoma were treated with two IC injections of AdCMV-PAI-1 given on days 7 and 9. Plasma was collected and the levels of human PAI-1 were quantified by capture ELISA. Results are expressed as mean ± SEM. There were 10 animals per group. ↑ = days of IC injections; ↓ = days of IV injections

Human PAI-1 plasma levels in mice treated with AdCMV-PAI-1 gene transfer. BALB/c nude mice bearing intraocular OCM-1 human uveal melanomas were treated with either two IC inoculations of either AdCMV-βGal or AdCMV-PAI-1 on days 7 and 9 post IC tumor inoculation or three IV inoculations of either AdCMV-PAI-1 or AdCMV-βGal on days 21, 28, and 35 post IC tumor inoculation. BALB/c nude mice bearing intraocular 99E1 melanoma were treated with two IC injections of AdCMV-PAI-1 given on days 7 and 9. Plasma was collected and the levels of human PAI-1 were quantified by capture ELISA. Results are expressed as mean ± SEM. There were 10 animals per group. ↑ = days of IC injections; ↓ = days of IV injections

Close Modal

or Create an Account

Close Modal
Close Modal